Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years

Indian Journal of Medical and Paediatric Oncology

Volumn 32, Issue 2, 2011, Pages 96-100

  Dikshit, Rajesh P ^a   Nagrani, Rajini ^a   Yeole, Balkrishna ^b   Koyande, Shravani ^b   Banawali, Shripad ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Indian Cancer Society   (India)

Author keywords

Chronic myeloid leukemia; estimated annual percentage change; imatinib

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CHILD; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ERROR; FEMALE; HUMAN; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREND STUDY;

EID: 82655170736     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.89792     Document Type: Article

References (29)

1. Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology. 6 th ed. New York: McGraw-Hill; 2001.
2. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukemia (CML). Best Pract Res Clin Haematol 2009;22:295-302.
3. Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiological burden of chronic myeloid leukemia. Expert Rev Anticancer Ther 2004;4:85-96. (Pubitemid 38208489)
4. National Cancer Registry Programme: Two years report of Population Based Cancer Registries 1999-2000. Indian Council of Medical Research, New Delhi 2005.
5. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, Available from: http://www.seer.cancer.gov/csr/1975- 2007/, [last cited on Nov 2009] SEER data submission, posted to the SEER web site, 2010.
6. Lee SJ. Chronic myelogenous leukemia. Br J Haematol 2000;111:993-1009.
7. McGuire TR, Kazakoff PW. Pharmacotherapy: A Pathophysiologic Approach. 4 th ed. NY, USA: Elsevier; 1999.
8. Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzoti V, Nanni O, et al. Alcohol consumption and risk of leukemia: A multicentre case control study. Leuk Res 2007;31:379-86. (Pubitemid 46073183)
9. Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2009;18:1501-6.
10. Biggs JC, Szer J, Crilley P, Aktinson K, Downs K, Dodds A, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992;80:1352-7.
11. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202-7. (Pubitemid 16183150)
12. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, et al. Favorable long term follow up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111:1039-43. (Pubitemid 351213381)
13. Hess G, Meyer RG, Schuch B, Bechthold K, El-Kholy I, Huber C. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: 15 year follow up. Am J Hematol 2008;83:178-84. (Pubitemid 351303939)
14. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, et al. Long term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working Party on CML. J Clin Oncol 2008;26:106-11.
15. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20. (Pubitemid 44394987)
16. Cancer incidence and mortality in Greater Mumbai 2005. Indian Cancer Society, 2009.
17. Census of India 2001, Series 14, Maharashtra, Provisional Population Totals, Paper 2, Director of Census Operation, 2001.
18. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Cancer Incidence in Five Continents. Vol. 9. Lyon: IARC Scientific Publications No. 160; 2007.
19. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987;6:449-67. (Pubitemid 17110908)
20. Yeole BB. An assessment of improvement in reliability and completeness of Mumbai cancer registry data from 1964-1997. Asian Pac J Cancer Prev 2001;2:225-32.
21. Parkin DM, Whelan SL, Ferlay J, Storm H, Teppo L, Thomas DM, editors. Cancer incidence in five continents. Vol. 1-8. Lyon, France: IARC Press; 2005.
22. Xie Y, Davies SM, Xiang Y, Robinson LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35. (Pubitemid 36444065)
23. McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: Time trends in the UK, 1984-93. Cancer Causes Control 1999;10:35-42. (Pubitemid 29134750)
24. Thygesen LC, Nielsen OJ, Johansen C. Trends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control 2009;20:1671-80.
25. Kwiatkowski A. Trends in incidence of leukemia in Poland, 1963-90: An epidemiological study. Eur J Cancer Prev 1994;3:277-83. (Pubitemid 24171981)
26. Cortes J. Natural History and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:569-84. (Pubitemid 38969132)
27. Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. J Manag Care Pharm 2007;13:8-12.
28. Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep 2008;10:365-71.
29. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Hematologica 2008;93:1544-9.